{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017310", "CSN": null, "TRF": "ORD_1233271_01", "MRN": "29266282", "PhysicianId": "34792", "NPI": "international"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "934021", "clinicalId": "935405", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1233271_01", "SampleName": "US1189763.01", "Version": "0", "Sample": {"FM_Id": "ORD_1233271_01", "SampleId": "US1189763.01", "BlockId": "S110-32958B", "TRFNumber": "ORD_1233271_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_11_08", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "70", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-89558", "MRN": "29266282", "FullName": "\u6797\u5ba5\u5747", "FirstName": "Yu_Chun", "LastName": "Lin", "SubmittedDiagnosis": "Metastatic olfactory neuroblastoma, Lymph nodes", "Gender": "Female", "DOB": "1968_07_29", "OrderingMD": "\u5f35\u7267\u65b0", "OrderingMDId": "34792", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lymph Node", "CollDate": "2021_09_29", "ReceivedDate": "2021-11-24 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Olfactory Neuroblastoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "8", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCOR", "isVUS": "true", "variantName": "T870S"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "A534N"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "G76A"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "R544C"}, {"geneName": "SMARCA4", "isVUS": "true", "variantName": "D1235G"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "S2306del"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H has been reported in 0.5% of pediatric neuroblastoma samples (Bonneville et al., 2017; 29850653). For patients with neuroblastoma whose treatment did not include stem cell transplant (SCT), higher MSI was significantly associated with worse outcome; if treatment included SCT, MSI>1 was significantly associated with improved 5_year event_free survival (EFS) whereas MSI=1 was not a predictor of EFS (Morgenstern et al., 2016; 27434878). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Neuroblastoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 0.4% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). In one study, patients with high or intermediate risk tumors had a higher average number of variants compared to low risk tumors (Padovan_Merhar et al., 2016; 27997549). Increased TMB has been reported in relapsed neuroblastoma samples compared to samples analyzed at diagnosis (Eleveld et al., 2015; 26121087). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "1", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "2", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "3", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "4", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "5", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "6", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "7", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "8", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "9", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "10", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "11", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "12", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "13", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "14", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "15", "ReferenceId": "27997549", "FullCitation": "Padovan_Merhar OM, et al. PLoS Genet. (2016) pmid: 27997549", "Include": "true"}, {"number": "16", "ReferenceId": "26121087", "FullCitation": "Eleveld TF, et al. Nat. Genet. (2015) pmid: 26121087", "Include": "true"}, {"number": "17", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "18", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "19", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "20", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "21", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "22", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "23", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "24", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "25", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "26", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "27", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "28", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "29", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "30", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "31", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "32", "ReferenceId": "27434878", "FullCitation": "Morgenstern DA, et al. Eur. J. Cancer (2016) pmid: 27434878", "Include": "true"}, {"number": "33", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "34", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "35", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "36", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_11_17 20:29:37", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "856x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": {"comment": {"commentedBy": "Erik Williams, M.D.", "commentedDts": "2021_11_17T20:28:19.000Z", "text": "This assay is not validated to delineate single copy losses or low_level copy gains; manual review of copy number data reveal numerous high_confidence segmental and chromosome_level copy number alterations. These findings are consistent with adequate tumor purity for detection of targetable alterations. However, no reportable alterations were detected in this specimen."}}, "AAC": {"Amendmends": {"Amendmend": {"ModifiedDts": "2021_11_18 20:20:46", "IsSigned": "true", "Comment": "This Corrected Report has been issued to update PHSYICIAN NAME from \"Yeh, Yi_Chen\" to \" Chang Mu_Hsin, Peter\u201d.", "Type": "Corrected"}}}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "HEAD OR NECK", "disease_ontology": "Head and neck esthesioneuroblastoma", "flowcell_analysis": "2000018776", "gender": "female", "pathology_diagnosis": "Olfactory neuroblastoma", "percent_tumor_nuclei": "70", "pipeline_version": "v3.8.2", "purity_assessment": "72.7", "specimen": "ORD_1233271_01*US1189763.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1233271_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lymph Node", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "919.2", "name": "SQ_US1189763.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4946", "cds_effect": "1600_1601GC>AA", "depth": "1106", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "49.46", "position": "chr7:2969678", "protein_effect": "A534N", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}, {"allele_fraction": "0.7622", "cds_effect": "3704A>G", "depth": "471", "equivocal": "false", "functional_effect": "missense", "gene": "SMARCA4", "percent_reads": "76.22", "position": "chr19:11144123", "protein_effect": "D1235G", "status": "unknown", "strand": "+", "transcript": "NM_003072", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}, {"allele_fraction": "0.6173", "cds_effect": "227G>C", "depth": "486", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "61.73", "position": "chr11:118307454", "protein_effect": "G76A", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}, {"allele_fraction": "0.3454", "cds_effect": "2609C>G", "depth": "1132", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "34.54", "position": "chrX:39931990", "protein_effect": "T870S", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}, {"allele_fraction": "0.1416", "cds_effect": "1630C>T", "depth": "473", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "14.16", "position": "chr19:15298126", "protein_effect": "R544C", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}, {"allele_fraction": "0.1045", "cds_effect": "6915_6917delCAG", "depth": "785", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "SPEN", "percent_reads": "10.45", "position": "chr1:16259649", "protein_effect": "S2306del", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1189763.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}